DEA Places Seizure Treatment Drug Into Schedule V
The Drug Enforcement Administration is placing the newly approved drug ganaxolone in Schedule V of the Controlled Substances Act, it said in an interim final rule. Effective June 1, ganaxolone, which was granted approval by the FDA in March, is…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
subject to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until July 1.